Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 6, 2010, Pages 798-809

  Yazbeck, Roger ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GROWTH HORMONE; IRINOTECAN; MOXIFLOXACIN; PLACEBO; SOMATOMEDIN; TEDUGLUTIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE HEMORRHAGIC PANCREATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CROHN DISEASE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG FATALITY; DRUG METABOLISM; DRUG SCREENING; ENTERITIS; GAMMA IRRADIATION; HEADACHE; HUMAN; IC 50; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NONHUMAN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SHORT BOWEL SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SWELLING; ULCERATIVE COLITIS;

CLINICAL TRIALS AS TOPIC; CROHN DISEASE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GLUCAGON-LIKE PEPTIDE 2; HUMANS; NAUSEA; PEPTIDES; SHORT BOWEL SYNDROME; TREATMENT OUTCOME; VOMITING;

EID: 79952952444     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Allelix reports Q3 1999 Results. Allelix Biopharmaceuticals Inc Press rele ASe 1999 July 09
2. The intestinotrophic properties of ALX-0600, a glucagon-like peptide-2 analogue. Yang ZJ, Burrowes C, Urlando C, Demchyshyn LL Gastroenterology 2000 118 4 Suppl 2 Abs 2880
3. An evaluation of single dose administration of ALX-0600, a GLP-2 analog, in healthy male subjects. Metcalfe AJ, Oliver SD, Dietrich J Gastroenterology 2000 118 4 Suppl 2 Pt 2 Abs 4973
4. GLP-2 augments the adaptive Response to massive intestinal Resection in rat. Scott RB, Kirk D, MacNaughton WK, Medding JB Am J Physiol-Gastrointest Liver Physiol 1998 275 5 Pt 1 G911-G921
5. Hormonal Therapy for short bowel syndrome. Sigalet DL, Martin GR J Pediatr SURG 2000 35 2 360-364 (Pubitemid 30082601) (Pubitemid 30082601)
6. Pharmacological and functional characterization of the human glucagon-like-peptide-2 receptor. Demchyshyn L, Colantonio CM, Liao LC, Tong S, Hahn SE, Lee DKH Gastroenterology 1999 116 4 Pt 2 A601
7. Characterization of the intestinotrophic effect of a glucagon-like peptide 2 (GLP-2) analogue in mice. Yang ZJ, Burrowes CE, Urlando C, Crivici A, Lee DKH FASEB J 1999 13 5 Pt 2 A807
8. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Drucker DJ, Ehrlich P, Asa SL, Brubaker PL Proc Natl Acad Sci USA 1996 93 7911-7916 (Pubitemid 26277138) (Pubitemid 26277138)
9. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. Hartmann B J Clin Endocrinol Metab 2000 85 8 2884-2888 (Pubitemid 32269168) (Pubitemid 32269168)
10. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH Gut 2000 47 1 112-119 (Pubitemid 30430419) (Pubitemid 30430419)
11. ALX-0600: A potent glucagon-like peptide-2 receptor agonist. Demchyshyn L L, Colantonio C M, Liao L, Burrowes C, Yang ZJ Gastroenterology 2001 120 5 Suppl 1 Abs 2589
12. ALX-0600, a dipeptidyl peptidase-IV Resistant glucagon-like peptide-2 (GLP-2) analog, improves intestinal function in short bowel syndrome (SBS) patients with a jejunostomy. Jeppesen PB, Blosch CM, Lopansri JB, Sanguinetti EL, Buchman AL, Scolapio JL, Ziegler TR, Howard L, Mortensen PB Gastroenterology 2002 122 4 Suppl 1 Abs S1249
13. ALX-0600, a glucagon-like peptide-2 (GLP-2) analog, enhances intestinal structure and function in patients with short bowel syndrome (SBS). Tappenden KA, Bartholome AL, Demchyshyn L, Lopansri J, Sanguinetti E, Blosch C, Lechago J Gastroenterology 2002 122 4 Suppl 1 Abs S1250
14. HoMologous desensitization of the human glucagon-like peptide-2 receptor in HEK293 cells. Maclean NA, Yu M, Demchyshyn LL Gastroenterology 2002 122 4 Suppl 1 Abs T918
15. ALX-0600, a glucagon-like peptide-2 analogue, protects small intestinal stem cells from radiation damage. Potter CS, Williamson S, Demchyshyn LL, Booth CS Gastroenterology 2003 124 Suppl 1 Abs W998
16. NPS Pharmaceuticals begins pivotal study with teduglutide in patients with short bowel syndrome. NPS Pharmaceuticals Inc Press rele ASe 2004 April 06
17. Teduglutide (ALX-0600), a dipeptidyl peptidase IV Resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB Gut 2005 54 9 1224-1231 (Pubitemid 41192479) (Pubitemid 41192479)
18. Effect of teduglutide on patients with moderate-severe Crohn's disease after 8 weeks of Therapy: A prospective double-blind, placebo controlled trial. Buchman Al, Katz S, Shnaidman M, Jacobs D Gastroenterology 2006 130 4 Suppl 2 Abs 686c
19. Teduglutide (ALX-0600), a glucagon-like peptide-2 (GLP-2) analogue inhibits contractility in the colon ex vivo. Demchyshyn LL, Wang H Gastroenterology 2006 130 4 Suppl 2 Abs W1605
20. Adalimumab for maintenance of clinical Response and remission in patients with Crohn's disease: The CHARM trial. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF Gastroenterology 2007 132 1 52-65 (Pubitemid 46108762) (Pubitemid 46108762)
21. NPS Pharmaceuticals reports 2006 Results and progRess, announces new business plan to advance pipeline. NPS Pharmaceuticals Inc Press rele ASe 2007 March 14
22. Teduglutide augments plasma citrulline, a marker of enterocyte mass in patients with Crohn's disease. Buchman AL, Kapikian R, Demchyshyn LL Gastroenterology 2007 132 4 Abs S1118
23. Teduglutide is a potent stimulus for intestinal adaptation in a neonatal piglet model of short bowel syndrome accompanied by parenteral nutrition Therapy. Tappenden KA, Chung BM Gastroenterology 2007 132 4 Abs S2201
24. NPS Pharmaceuticals and Nycomed announce licensing agreement for Gattex in territories outside North America. NPS Pharmaceuticals Inc Press rele ASe 2007 September 26
25. Nycomed Confrms commitment to Gattex partnership; NPS to receive $25 million payment. NPS Pharmaceuticals Inc Press rele ASe 2007 October 31
26. Teduglutide, a novel GLP-2 analog, in the management of short bowel syndrome (SBS) patients dependent on parenteral nutrition: A multicenter, multinational placebo-controlled clinical trial. O'Keefe SJ, Gilroy R, Jeppesen PB, Messing B, Allard JP, Seidner DL, Pertkiewicz M, Kapikian R, McGraw N, Caminis J Gastroenterology 2008 134 4 Abs 212
27. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, improves fuid balance in short bowel syndrome (SBS) patients depending on parenteral support (PN). Jeppesen PB, Messing B, Pertkiewicz M, Cyran J, Demchyshyn LL, Kershner R Gastroenterology 2008 103 Suppl Abs 757
28. Teduglutide, a GLP-2 analog enhances intestinal structure in short bowel syndrome (SBS) patients dependent on parenteral nutrition (PN). Tappenden K, Pertkiewicz M, Gilroy R, Allard J, Kunecki M, Sauerwein H, Mc-Graw N, Bekker P, Messing B AM J Gastroenterol 2008 103 Suppl 1 Abs 272
29. Pharmacokinetic/pharmacodynamic correlation between teduglutide, an analog of GLP-2, and citrulline, a biomarker of small intestinal enterocyte functional mass in short bowel patients. Messing B, Mouksassi S, Jeppesen PB, Joly F, Demchyshyn L, Cyran J, Marier JF AM J Gastroenterol 2008 103 Suppl Abs OP234
30. Treatment out to 1 year with a GLP-2 analog, teduglutide, safely reduces parenteral nutrition (PN) needs in PN-dependent short bowel syndrome (SBS) patients. Gilroy R, Allard J, Jeppesen PB, Seidner D, Pertkiewicz M, Howard L, Keefe SO, McGraw N, Messing B, Jeejeebhoy K AM J Gastroenterol 2008 103 Suppl Abs 273
31. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. Marier JF, Beliveau M, Mouksassi MS, Shaw P, Cyran L, Kesavan J, Wallens J, Zahir H, Wells D, Caminis J J Clin Pharmacol 2008 48 11 1289-1299
32. Continuous intravenous administration of teduglutide (ALX-0600), a glucagon-like peptide-2 (GLP-2) analog induces intestinotrophic activity. Demchyshyn LL, Teuscher N, Wells DS AM J Gastroenterol 2007 102 Suppl 2 Abs 250
33. Effcacy and safety of teduglutide in parenteral nutrition (PN)-dependent SBS subjects: Update of a current multinational trial. Gilroy R, Pehlinov N, Cyran J, McGraw N, Kapikian R, Demchyshyn L, Caminis J AM J Gastroenterol 2007 102 Suppl 2 Abs 919
34. Pharmacokinctics and safety profle of a range of teduglutide doses given for eight days in healthy volunteers. Pehlivanov N, Wallens J, Yang J, Cyran J, Wells D AM J Gastroenterol 2007 102 Suppl 2 Abs 258
35. Effect of teduglutide in patients with moderate-severe Crohn's disease after 20 weeks of daily Therapy. Buchman AL, Katz S, Shnaidman M, Jacobs D AM J Gastroenterol 2006 101 9 Suppl S Abs 1190
36. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS Cell Prolif 2004 37 6 385-400 (Pubitemid 39577267) (Pubitemid 39577267)
37. NPS Pharmaceuticals initiates phase 3 'STEPS' study to Confrm Gattex reduces parenteral nutrition dependence in short bowel syndrome. NPS Pharmaceuticals Inc Press rele ASe 2008 December 02
38. Effects of treatment with glucagon-like peptide-2 on bone Resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Gottschalck IB, Jeppesen PB, Hartmann B, Holst JJ, Henriksen DB Scand J Gastroenterol 2008 43 11 1304-1310
39. NPS Pharmaceuticals reports third quarter Results and improved cash burn guidance. NPS Pharmaceuticals Inc Press rele ASe 2009 November 04
40. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Kouris GJ, Liu Q, Rossi H, Djuricin G, Gattuso P, Nathan C, Weinstein RA, Prinz RA AM J SURG 2001 181 6 571-575 (Pubitemid 32769988) (Pubitemid 32769988)
41. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. Marier JF, Mouksassi MS, Gosselin NH, Beliveau M, Cyran J, Wallens J J Clin Pharmacol 2010 50 1 36-49
42. Clinical trial simulations in pediatric patients using realistic covariates: Application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Mouksassi MS, Marier JF, Cyran J, Vinks AA Clin Pharmacol Ther 2009 86 6 667-671
43. The use of GLP-2 and related growth factors in intestinal diseases. Yazbeck R, Abbott CA, Howarth GS Curr Opin InvestIG DrugS 2010 11 4 440-446
44. Biologic Therapy for infammatory bowel disease. Ardizzone S, Porro GB DrugS 2005 65 16 2253-2286 (Pubitemid 41571985) (Pubitemid 41571985)
45. NPS Pharmaceuticals announces completion of patient randomization in phase 3 STEPS study of Gattex in short bowel syndrome. NPS Pharmaceuticals Inc Press rele ASe 2010 July 22
46. NPS Pharmaceuticals Inc Q2 2010 earnings Conference call tranScript. NPS Pharmaceuticals Inc COMPANY PReseNTATION 2010 August 04
47. NPS Pharmaceuticals: Partnering opportunities. NPS Pharmaceuticals Inc COMPANY World WIDE WEB SITE 2010 September 06
48. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG, Teduglutide SG Inflamm Bowel Dis 2010 16 6 962-973
49. The infuence of teduglutide, a novel GLP-2 analogue, on energy absorption in short bowel syndrome (SBS) patients dependent on parenteral nutrition (PN). Jeppesen PB, Tappenden KA, Gilroy R, O'Keefe SJ, Seidner DL, McGraw N, Chu H, Messing B Gastroenterology 2009 136 5 Abs 1281
50. Teduglutide, a novel GLP-2 analogue, decreases fecal wet weight, sodium and potassium excretion in short bowel syndrome (SBS) patients dependent on parenteral nutrition (PN). Jeppesen PB, Tappenden KA, Gilroy R, O'Keefe SJ, Seidner DL, McGraw N, Chu H, Messing B GASTrOeNTerOlOGY 2009 136 5 Abs 897
51. Teduglutide (TG), a dipeptidyl-peptidase IV Resistant glucagon-like peptide 2 (GLP-2) analogue, improves lean body mass and total bone mineral content in short bowel patients (SBS) depending on home parenteral nutrition (PN). Dual energy X-ray absorptiometry (DEXA) Results from a randomized, placebo-controlled, 24-weeks study. Jeppesen P, O'Keefe S, Gilroy R, Seidner D, Messing B AM J Gastroenterol 2009 104 Suppl 3 Abs 1121
52. Teduglutide (TG) improves electrolyte and wet weight absorption in short bowel syndrome (SBS) patients, but this is not correlated to increases in plasma citrulline (PC). Jeppesen P, O'Keefe S, Gilroy R, Seidner D, Messing B AM J Gastroenterol 2009 104 Suppl 3 Abs 1112
53. Citrulline: A potential predictor of reductions in parenteral nutrition achieved in chronic parenteral nutrition dependant patients with short bowel syndrome (SBS) treated with teduglutide. Gilroy R, O'Keefe SJ, McGraw N, Chu H, Jeejeebhoy KN, Messing B Gastroenterology 2009 136 5 Abs 898
54. Treatment with teduglutide, a GLP-2 analog, for up to 1 year was safe and signifcantly reduced parenteral nutrition (PN) needs in PN-dependent short bowel syndrome (SBS) patients. Jeppesen PB, Pertkiewicz M, Jeejeebhoy K, Gabe S, Allard J, Sauerwein H, Joly F, McGraw N, Gilroy R, Messing B Gut 2008 57 Suppl 2 Abs OP229
55. Teduglutide, a glucagon-like peptide-2 analog, enhances intestinal structure in short bowel syndrome (SBS) patients dependent on parenteral nutrition (PN). Tappenden KA, Pertkiewicz M, Gilroy R, Allard J, Kunecki M, McGraw N, Sauerwein H, Jeppesen P, Messing B Gut 2008 57 Suppl 2 Abs 272
56. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. Walsh NA, Yusta B, Dacambra MP, Anini Y, Drucker DJ, Brubaker PL Endocrinology 2003 144 10 4385-4392 (Pubitemid 37204837) (Pubitemid 37204837)
57. Glucagon-like peptide (GLP)-2 reduces chemoTherapy-associated mortality and enhances cell survival in cells expRessing a transfected GLP-2 receptor. Boushey RP, Yusta B, Drucker DJ Cancer 2001 61 2 687-693 (Pubitemid 32128634) (Pubitemid 32128634)
58. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Lovshin J, Yusta B, Iliopoulos I, Migirdicyan A, Dableh L, Brubaker PL, Drucker DJ Endocrinology 2000 141 11 4194-4201
59. Enzymatic-and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. TavaRes W, Drucker DJ, Brubaker PL Am J Physiol-Endocrinol Metab 2000 278 1 E134-E139 (Pubitemid 30101930) (Pubitemid 30101930)
60. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Boushey RP, Yusta B, Drucker DJ Am J Physiol-Endocrinol Metab 1999 277 5 Pt 1 E937-E947
61. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Drucker DJ, Shi Q, Crivici A, SumnerSmith M, TavaRes W, Hill M, DeFoRest L, Cooper S, Brubaker PL Nat Biotechnol 1997 15 7 673-677 (Pubitemid 27291170) (Pubitemid 27291170)
62. Chronic administration of glucagon-like peptide-2 (GLP-2) alters murine intestinal enterocyte form and function. Benjamin MA, Yang PC, McKay DM, Perdue M Gastroenterology 1999 116 4 Abs 2868
63. Clinical aspects and pathophysiology of infammatory bowel disease. Hendrickson BA, Gokhale R, Cho JH Clin MICROBiol Rev 2002 15 1 79-94 (Pubitemid 34052583) (Pubitemid 34052583)
64. Review article: Infiximab Therapy for infammatory bowel disease-Seven years on. Rutgeerts P, Van Assche G, Vermeire S AlIMeNT Pharmacol Ther 2006 23 4 451-463 (Pubitemid 43381999) (Pubitemid 43381999)
65. Effcacy of adalimumab for the management of infammatory bowel disease in the clinical setting. Trinder MW, Lawrance IC J Gastroenterol Hepatol 2009 24 7 1252-1257
66. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofbroblasts with GLP-2 receptors. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ REGUL PEPT 2005 124 1-3 105-112 (Pubitemid 39488347) (Pubitemid 39488347)
67. Intestinal Response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Drucker DJ, DeFoRest L, Brubaker PL Am J Physiol-Gastrointest Liver Physiol 1997 273 6 Pt 1 G1252-G1262
68. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Drucker DJ, Yusta B, Boushey RP, DeFoRest L, Brubaker PL AM J PHYSIOl-Gastrointest Liver Physiol 1999 276 1 Pt 1 G79-G91 (Pubitemid 29063603) (Pubitemid 29063603)
69. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Iakoubov R, Lauffer LM, Trivedi S, Kim YIJ, Brubaker PL Endocrinology 2009 150 9 4033-4043
70. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Thulesen J, Hartmann B, Hare KJ, Kissow H, Orskov C, Holst JJ, Poulsen SS Gut 2004 53 8 1145-1150 (Pubitemid 38961969) (Pubitemid 38961969)
71. Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ Cancer Res 2008 68 19 7897-7904
72. GLP-2 augments the adaptive Response to massive intestinal Resection in rat. Scott RB, Kirk D, MacNaughton WK, Meddings JB Gastroenterology 1998 114 4 Abs G3722
73. Glucagon-like peptide-2 (GLP-2) reduces intestinal epithelial permeability of both the paracellular and transcellular pathway. Benjamin MA, McKay DM, Perdue MH Gastroenterology 1998 114 4 Abs G4620
74. Enhancement of intestinal epithelial repair by a human glucagon-like peptide-2 analogue, h[Gly2]-GLP-2, in a murine model of ulcerative colitis. Drucker DJ, DeFoRest L, Yusta B, Brubaker PL Gastroenterology 1998 114 4 Abs G3968
75. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ Am J Physiol-Endocrinol Metab 1997 273 1 E77-E84
76. Administration of the protease-Resistant glucagon-like peptide 2 analog, [GLY2]GLP-2, prior to and concurrently with the chemoTherapeutic agent, 5-fuorouracil, inhibits small intestinal atrophy and attenuates bodyweight loss in mice. Petersen YM, Larsen BD, Petersen JS Gastroenterology 2005 128 Abs S1297
77. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB Gastroenterology 2001 120 4 806-815 (Pubitemid 32193176) (Pubitemid 32193176)
78. The use of hormonal growth factors in the treatment of patients with short-bowel syndrome. Jeppesen PB DrugS 2006 66 5 581-589 (Pubitemid 43671452) (Pubitemid 43671452)
79. GLP-2 analog, teduglutide, improves fuid balance in short bowel syndrome (SBS) patients dependent on parenteral nutritional (PN). Jeppesen PB, Pertkiewicz M, Allard J, Jeejeebhoy K, McGraw N, Gilroy R, Messing B AM J Gastroenterol 2008 103 Suppl Abs OP228
80. Mortality and economics in short bowel syndrome. Schalamon J, Mayr JM, Hollwarth ME BEST PRACT Res Clin Gastroenterol 2003 17 6 931-942
81. The economic costs of Crohn's disease and ulcerative colitis. Australian Crohn's and Colitis Association WEB SITE 2007 June 09
82. Short bowel syndrome: Defnition, causes, intestinal adaptation and bacterial overgrowth. Pomar MDB, Casariego AV NUTRICION HOSPITALARIA 2007 22 74-85
83. Bowel Resection induced intestinal adaptation: ProgRess from bench to bedside. Longshore SW, Wakeman D, McMellen M, Warner BW MINERVA Pediatr 2009 61 3 239-251
84. Management of the short bowel syndrome after extensive small bowel Resection. Keller J, Panter H, Layer P Best Pract Res Clin Gastroenterol 2004 18 5 977-992 (Pubitemid 39378183) (Pubitemid 39378183)
85. Intestinal transplant: The long and short of it. Lennon E J INFUS NURS 2010 33 6 391-397
86. AGA technical review on short bowel syndrome and intestinal transplantation. Buchman AL, Scolapio J, Fryer J Gastroenterology 2003 124 4 1111-1134 (Pubitemid 36389810) (Pubitemid 36389810)
87. Enhancing bowel adaptation in short bowel syndrome. Jeppesen PB, Mortensen PB Curr Gastroenterol Rep 2002 4 4 338-347
88. GLP-2 administration Results in increased proliferation but paradoxically an adverse outcome in a juvenile piglet model of short bowel syndrome. Pereira-Fantini PM, Nagy TS, Thomas SL, Taylor RG, Sourial M, Paris MCJ, Holst JJ, Fuller PJ, Bines JE J Pediatr Gastroenterol Nutr 2008 46 120-28